We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.
Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.
Must meet criteria of the high-risk population as described with one of the below criteria
≥ 30 years AND
first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.
Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer '
• Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy.
Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia
Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test.
Tel-Aviv Sourasky Medical Center
Lead sponsor
Dana-Farber Cancer Institute
Collaborator